HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Developer Of First US OTC COVID-19 Antigen Test Plans 'Digital Diagnostics For Multitude Of Infectious Diseases'

Executive Summary

The developer of the OTC at-home antigen test — the first of its kind to get an emergency use authorization from the FDA – received more than $200m from the US government to manufacture in the US. So what’s next for Ellume? In this Q&A, the Australian company’s CEO, Sean Parson, explains.

You may also be interested in...



US Supply Of OTC COVID-19 Tests Gets Boost Through $231.8M Contract For Australian Firm

Biden administration seems to be betting Elluve's OTC at-home antigen diagnostic test will be a game changer in helping stop the spread of the coronavirus.

Biden Admin Pays Ellume $231M To Build COVID-19 US Test Plant

The government seems to be betting the company’s over-the-counter at-home antigen diagnostic test will be a game changer in stopping the spread of the coronavirus.

Massive Family Dollar Rat Infestation Leads To Multi-State Recall

The US FDA found more than 2,000 rats at an Arkansas Family Dollar distribution center, leadingto a six-state recall for products including feminine hygiene products, contact lens cleaners and face masks.

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS151289

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel